164 results on '"A. Finel"'
Search Results
2. Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
- Author
-
Berning, Philipp, primary, Ngoya, Maud, additional, Schmitz, Norbert, additional, Finel, Hervé, additional, Boumendil, Ariane, additional, Kim, Won-Seog, additional, Wang, Fengrong, additional, Huang, Xiao-jun, additional, Hermine, Olivier, additional, Philippe, Laure, additional, Couronne, Lucile, additional, Jaccard, Arnaud, additional, Liu, Daihong, additional, Wu, Depei, additional, Reinhardt, Hans Christian, additional, Chalandon, Yves, additional, Wagner, Eva Maria, additional, Kwon, Mi, additional, Zhang, Xi, additional, Carpenter, Ben, additional, Yakoub-Agha, Ibrahim, additional, Wulf, Gerald, additional, López Jiménez, Javier, additional, Sanz, Jaime, additional, Labussière-Wallet, Hélène, additional, Shimoni, Avichai, additional, Dreger, Peter, additional, Sureda, Anna, additional, and Glass, Bertram, additional
- Published
- 2022
- Full Text
- View/download PDF
3. Graft-Versus-Host-Disease Prophylaxis with ATG or Ptcy in Patients with Lymphoproliferative Disorders Undergoing Reduced Intensity Conditioning Regimen 9/10 Mmud HCT
- Author
-
Paviglianiti, Annalisa, primary, Mussetti, Alberto, additional, Ngoya, Maud, additional, Boumendil, Ariane, additional, Gulbas, Zafer, additional, Ciceri, Fabio, additional, Bonifazi, Francesca, additional, Russo, Domenico, additional, Fegueux, Nathalie, additional, Stölzel, Friedrich, additional, Bulabois, Claude-Eric, additional, Socie, Gerard, additional, Forcade, Edouard, additional, Solano, Carlos, additional, Finel, Hervé, additional, Robinson, Stephen, additional, Montoto, Silvia, additional, and Glass, Bertram, additional
- Published
- 2022
- Full Text
- View/download PDF
4. Real Life Analysis of Brentuximab Vedotin (BV) Use As Consolidation Therapy in Patients with Hodgkin's Lymphoma (HL) with High Risk of Relapse after Autologous Stem Cell Transplantation (ASCT). a Retrospective Analysis of the EBMT Lymphoma Working Party
- Author
-
Martinez Munoz, Maria Carmen, primary, Bastos-Oreiro, Mariana, additional, Boumendil, Ariane, additional, Finel, Hervé, additional, Bazarbachi, Ali, additional, Alzahrani, Mohsen, additional, Illes, Arpad, additional, Blaise, Didier, additional, Sakellar, Ioanna, additional, Solano, Carlos, additional, Pulsoni, Alessandro, additional, Zuckerman, Tsila, additional, Durakovic, Nadira, additional, Castagna, Luca, additional, Sica, Simona, additional, Guidez, Stéphanie, additional, Bourhis, Jean-Henri, additional, García-Sanz, Ramón, additional, Cemm Ar, Muhlis, additional, Stamatoulas Bastard, Aspasia, additional, Briones, Javier, additional, Aktar, Saad, additional, Ram, Ron, additional, Heras, Inmaculada, additional, Rubio, Marie Thérèse, additional, Petrini, Mario, additional, Ojeda-Uribe, Mario, additional, Glass, Bertram, additional, and Sureda, Anna, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT
- Author
-
Sureda, Anna, primary, Boumendil, Ariane, additional, Berning, Philipp, additional, Finel, Hervé, additional, Caillot, Denis, additional, Roesler, Wolf, additional, Finke, Jürgen, additional, Blau, Igor Wolfgang, additional, Leblond, Veronique, additional, Bittenbring, Joerg, additional, Tsoulkani, Anna, additional, Carpenter, Ben, additional, Nagler, Arnon, additional, Blaise, Didier, additional, Dreger, Peter, additional, and Schmitz, Norbert, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Trends in the Use of Hematopoietic Stem Cell Transplantation in the Management of Relapsed/Refractory Diffuse Large B Cell Lymphoma. a Retrospective Analysis of the Lymphoma Working Party of the EBMT
- Author
-
Anna Sureda, Ariane Boumendil, Philipp Berning, Hervé Finel, Denis Caillot, Wolf Roesler, Jürgen Finke, Igor Wolfgang Blau, Veronique Leblond, Joerg Bittenbring, Anna Tsoulkani, Ben Carpenter, Arnon Nagler, Didier Blaise, Peter Dreger, and Norbert Schmitz
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
7. Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
- Author
-
Philipp Berning, Maud Ngoya, Norbert Schmitz, Hervé Finel, Ariane Boumendil, Won-Seog Kim, Fengrong Wang, Xiao-jun Huang, Olivier Hermine, Laure Philippe, Lucile Couronne, Arnaud Jaccard, Daihong Liu, Depei Wu, Hans Christian Reinhardt, Yves Chalandon, Eva Maria Wagner, Mi Kwon, Xi Zhang, Ben Carpenter, Ibrahim Yakoub-Agha, Gerald Wulf, Javier López Jiménez, Jaime Sanz, Hélène Labussière-Wallet, Avichai Shimoni, Peter Dreger, Anna Sureda, and Bertram Glass
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
8. Graft-Versus-Host-Disease Prophylaxis with ATG or Ptcy in Patients with Lymphoproliferative Disorders Undergoing Reduced Intensity Conditioning Regimen 9/10 Mmud HCT
- Author
-
Annalisa Paviglianiti, Alberto Mussetti, Maud Ngoya, Ariane Boumendil, Zafer Gulbas, Fabio Ciceri, Francesca Bonifazi, Domenico Russo, Nathalie Fegueux, Friedrich Stölzel, Claude-Eric Bulabois, Gerard Socie, Edouard Forcade, Carlos Solano, Hervé Finel, Stephen Robinson, Silvia Montoto, and Bertram Glass
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
9. Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study
- Author
-
Mussetti, Alberto, primary, Kanate, Abraham S., additional, Wang, Tao, additional, He, Meilun, additional, Hamadani, Mehdi, additional, Finel, Hervé, additional, Boumendil, Ariane, additional, Glass, Bertram, additional, Castagna, Luca, additional, Blaise, Didier, additional, Marsh, Steven G.E., additional, Paczesny, Sophie, additional, Gadalla, Shahinaz M., additional, Dreger, Peter, additional, Spellman, Stephen R., additional, Lee, Stephanie J., additional, Bolon, Yung-Tsi, additional, and Sureda, Anna, additional
- Published
- 2021
- Full Text
- View/download PDF
10. Haploidentical Vs. Matched Unrelated Donor Transplants Using Post-Transplant Cyclophosphamide for Lymphoma: A Joint CIBMTR/EBMT Study
- Author
-
Stephen R. Spellman, Peter Dreger, Didier Blaise, Shahinaz M. Gadalla, Stephanie J. Lee, Ariane Boumendil, Bertram Glass, Steven G.E. Marsh, Meilun He, Anna Sureda, Luca Castagna, Mehdi Hamadani, Sophie Paczesny, Abraham S. Kanate, Yung-Tsi Bolon, Alberto Mussetti, Tao Wang, and Herve Finel
- Subjects
medicine.medical_specialty ,Post transplant cyclophosphamide ,business.industry ,Immunology ,medicine ,Cell Biology ,Hematology ,Matched Unrelated Donor ,medicine.disease ,business ,Biochemistry ,Lymphoma ,Surgery - Abstract
Introduction: Post-transplant cyclophosphamide (PTCy) is a standard GVHD prophylactic approach for haploidentical hematopoietic cell transplantation (haploHCT). Retrospective studies in patients with lymphoma showed lower chronic GVHD in haploHCT with PTCy-based GVHD prophylaxis compared to matched unrelated donor (MUD) HCT with calcineurin-based GVHD prophylaxis (+/- ATG). Recent retrospective studies showed that using MUD donors was better than haplo donors when PTCy and reduced-intensity conditioning are used for ALL, AML or MDS. However, no studies to date have compared haploHCT and MUD HCT when PTCy is used in the setting of lymphomas. Methods: 2155 adults (730 CIBMTR, 1425 EBMT) aged =/>18 years who received their first haploHCT or MUD HCT (8/8 match at HLA-loci A, B, C and DRB1) using PTCy from 2010-2019 for lymphoma were included. The majority of both MUD (n=312; 14%) and haplo (n=1843; 86%) HCTs received reduced intensity/non-myeloablative conditioning (n=1655; 77%) using a peripheral blood stem cell graft (n=1379; 64%) and a three-drug GVHD prophylaxis (PTCy + calcineurin inhibitor + MMF, n=1805; 84%). Hodgkin's lymphoma was the most common indication (n=899; 42%) followed by diffuse large B-cell lymphoma (n=525; 24%), T-cell lymphomas (n=328; 15%), mantle cell lymphoma (n=234; 11%) and follicular lymphoma (n=169; 8%). Most had chemosensitive disease at transplant (n=1781; 83%). Some main characteristics of the two cohorts are shown in Figure 1. Median follow-up among survivors was longer for haplo-HCT (36 and 31 months for the CIBMTR and EBMT cohort, respectively) than MUD-HCT (24 and 17 months, respectively). Cox proportional hazards models were built using stepwise forward and backward selection with a selection/retention threshold of 0.05. Any clinical variables that did not meet the proportional hazard assumption were adjusted for by stratification, and regression models were built to compare outcomes between donor types. Center effect was adjusted in all the models. Results: Figures 2 and 3 show the multivariate analysis results. Overall survival was 73% (71-75%) at 1 year and 65% (63-67%) at 2 years. Relapse was 21% (20-23%) at 1 year and 26% (24-28%) at 2 years. All outcomes favored MUD over haplo donors with the use of PTCy-based GVHD prophylaxis for both. Conclusions: Patients with lymphoma receiving PTCy HCT from MUDs demonstrated better outcomes than those with haplo donors in this retrospective study of CIBMTR and EBMT data Future prospective studies are needed to confirm and clarify the reasons for these differences. Figure 1 Figure 1. Disclosures Mussetti: GILEAD: Other: Clinical trials participation, Research Funding; TAKEDA: Honoraria; NOVARTIS: Honoraria, Other: Clinical trials participation. Hamadani: Janssen, Incyte, ADC Therapeutics, Omeros, Morphosys, Kite: Consultancy; Sanofi, Genzyme, AstraZeneca, BeiGene: Speakers Bureau; Takeda, Spectrum Pharmaceuticals and Astellas Pharma: Research Funding. Glass: Novartis: Consultancy; Riemser: Research Funding; Helios Klinik Berlin-Buch: Current Employment; Kite: Consultancy; Roche: Consultancy, Research Funding, Speakers Bureau; BMS: Consultancy. Blaise: Jazz Pharmaceuticals: Honoraria. Paczesny: Medical University of South Carolina: Patents & Royalties: inventor on the ST2 bispecific antibody patent application. Dreger: Novartis: Consultancy, Speakers Bureau; Riemser: Consultancy, Research Funding, Speakers Bureau; BMS: Consultancy; Bluebird Bio: Consultancy; AstraZeneca: Consultancy, Speakers Bureau; Gilead Sciences: Consultancy, Speakers Bureau; Janssen: Consultancy; AbbVie: Consultancy, Speakers Bureau; Roche: Consultancy, Speakers Bureau. Lee: AstraZeneca: Research Funding; Incyte: Research Funding; Janssen: Other; Kadmon: Research Funding; National Marrow Donor Program: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Syndax: Research Funding; Pfizer: Research Funding; Takeda: Research Funding; Amgen: Research Funding. Sureda: BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Speakers Bureau; Bluebird: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Support for attending meetings and/or travel, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Kite, a Gilead Company: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Consultancy, Honoraria, Speakers Bureau; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Mundipharma: Consultancy; Roche: Other: Support for attending meetings and/or travel; GSK: Consultancy, Honoraria, Speakers Bureau.
- Published
- 2021
11. Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years
- Author
-
Bazarbachi, Ali, primary, Boumendil, Ariane, additional, Finel, Hervé, additional, Khvedelidze, Irma, additional, Romejko-Jarosinska, Joanna, additional, Tanase, Alina Daniela, additional, Akhtar, Saad, additional, Ben Othman, Tarek, additional, Tbakhi, Abdelghani, additional, Afanasyev, Boris, additional, Briones, Javier, additional, Gülbas, Zafer, additional, Elcheikh, Jean, additional, Hamladji, Rose-Marie, additional, Elverdi, Tugrul, additional, Blaise, Didier, additional, Martinez, Carmen, additional, Alma, Eleonora, additional, Halaburda, Kazimierz, additional, Botelho de Sousa, Aida, additional, Glass, Bertram, additional, Robinson, Stephen, additional, Montoto, Silvia, additional, and Sureda Balari, Anna, additional
- Published
- 2020
- Full Text
- View/download PDF
12. NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry
- Author
-
Bekadja, Mohamed Amine, primary, Boumendil, Ariane, additional, Blaise, Didier, additional, Chevalier, Patrice, additional, Peggs, Karl S, additional, Salles, Gilles, additional, Giebel, Sebastian, additional, Finke, Jürgen, additional, Arcese, William, additional, Milpied, Noel, additional, Finel, Hervé, additional, and Gorin, Norbert Claude, additional
- Published
- 2020
- Full Text
- View/download PDF
13. Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years
- Author
-
Joanna Romejko-Jarosinska, Rose-Marie Hamladji, Boris V. Afanasyev, Silvia Montoto, Eleonora Alma, Carmen Martinez, Tugrul Elverdi, Aida Botelho Sousa, Herve Finel, Didier Blaise, Bertram Glass, Irma Khvedelidze, Javier Briones, Ali Bazarbachi, Tarek Ben Othman, Ariane Boumendil, Kazimierz Hałaburda, Jean El-Cheikh, Alina Tanase, Abdelghani Tbakhi, Anna Sureda Balari, Zafer Gulbas, Stephen D. Robinson, and Saad Akhtar
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Early Relapse ,Cell Biology ,Hematology ,Pembrolizumab ,Biochemistry ,Autologous stem-cell transplantation ,Interquartile range ,Internal medicine ,medicine ,Hodgkin lymphoma ,Nivolumab ,Stem cell ,Brentuximab vedotin ,business ,medicine.drug - Abstract
Salvage chemotherapy and autologous stem cell transplantation (auto-SCT) results in the cure of around 50% of patients with Hodgkin lymphoma (HL) failing first line therapy. In historical data, patients who progressed after auto-SCT had a poor outcome, with a median overall survival (OS) of around 1-2 years. Significant progress has been achieved in the last decade with the use of brentuximab vedotin (BV) or check-point inhibitors (CPI) and the increasing use of haploidentical transplant. However, little information is available about the characteristics and real-world outcomes of patients with HL relapsing after auto-SCT in the current era. To assess prognosis of patients with recurrent-HL post auto-SCT over time, we analyzed the European Blood and Marrow Transplant registry data of 1781 adult HL patients who relapsed between 2006 and 2017 after a first auto-SCT. A specific questionnaire was sent to all participant centers to obtain additional data regarding characteristics of the patients, treatment of relapse and outcome after auto-SCT failure. Detailed data were collected for 760 patients [median age 32; interquartile range (IQR) 25-42] included in this study. After a median follow-up for alive patients of 57 months (IQR: 29-89), the 4-year OS after relapse for the 760 included patients was 46% (95%CI: 43-50) and similar to that of 1021 non-included patients (45%, 95%CI: 41-48). The 4-year OS after relapse continuously increased from 35% (95%CI: 27-45) for 136 patients relapsing in 2006-2008, to 43% (95%CI: 37-49) for 258 patients relapsing in 2009-2011, 49% (95%CI: 43-56) for 238 patients relapsing in 2012-2014, and 61% (95%CI: 52-72) for 128 patients relapsing in 2015-2017 (p=0.001) (Figure 1). Improvement over time was predominantly noted in patients who had an early relapse (within 12 months) after auto-SCT (p=0.01) but not in those with a late relapse (p=0.6). On multivariate analysis, patients who relapsed in more recent years and those with a longer interval from transplant to relapse had a better OS, whereas increasing age, poor performance status at relapse, bulky disease at relapse, extranodal disease at relapse and presence of B-symptoms at relapse were associated with a worse OS. Regarding treatment at relapse, BV was used in 233 patients (31%) after a median of 2 months from relapse (IQR: 0.8-8), predominantly as first treatment of relapse (155 patients). BV use increased over the 4 time periods from 3% to 19%, 49% and 49% respectively, and resulted in a complete remission (CR) in 46% and a partial response (PR) in 32%. The 4-year OS from BV use for relapse after auto-SCT was 56% (95%CI: 49-64). CPI were used in 91 patients (12%) including nivolumab in 75 patients and pembrolizumab in 12 patients after a median of 18 months from relapse (IQR: 5-35). CPI use increased over the 4 time periods from 1% to 4%, 14% and 35% respectively, and resulted in a CR of 44%, PR 32%, with a 4-year OS from CPI use of 44% (95%CI: 30-63). Finally, a second SCT (SCT2) was performed in 330 patients (43%) predominantly allogeneic SCT (285 patients, 86%) including a haploidentical SCT in 54 patients (16%). SCT2 was performed in 40% and 37% of patients relapsing in 2006-2008 and 2009-2011 respectively but its use increased to 49% and 51% of patients relapsing in 2012-2014 and 2015-2017 respectively. Four-year OS after SCT2 was 55%. In conclusion, outcome after post-transplant relapse has improved significantly in recent years, particularly in the case of early relapse, possibly reflecting, among other factors, the efficacy of post-transplant salvage including BV, CPI and second transplant. These large-scale real-world data can serve as benchmark for future studies in that setting. Figure 1 Disclosures Blaise: Jazz Pharmaceuticals: Honoraria. Sureda Balari:Incyte: Consultancy; Celgene: Consultancy, Honoraria; BMS: Speakers Bureau; Roche: Honoraria; Sanofi: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Gilead/Kite: Consultancy, Honoraria; Merck Sharpe and Dohme: Consultancy, Honoraria, Speakers Bureau; Celgene/Bristol-Myers Squibb: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria.
- Published
- 2020
14. NON Cryopreserved Hematopoietic STEM CELLS to Autograft Patients with Lymphomas: A PAIR Matched Analysis Comparing a Single Center Experience to the Use of Cryopreserved STEM CELLS Reported to the EBMT Registry
- Author
-
Mohamed Amine Bekadja, Gilles Salles, Norbert Claude Gorin, Karl S. Peggs, William Arcese, Noel Milpied, Sebastian Giebel, Didier Blaise, Patrice Chevalier, Jürgen Finke, Herve Finel, and Ariane Boumendil
- Subjects
medicine.medical_specialty ,Neutrophil Engraftment ,business.industry ,Immunology ,Cell Biology ,Hematology ,Single Center ,medicine.disease ,Biochemistry ,Cryopreservation ,Haematopoiesis ,Autologous stem-cell transplantation ,Internal medicine ,Medicine ,Progression-free survival ,Stem cell ,business ,Multiple myeloma - Abstract
Introduction: Around fifty thousand autologous stem cell transplantations are done each year worldwide, using cryopreserved peripheral blood stem cells (PBSC). Cryopreservation is time consuming and expensive. Since 2007, several retrospective studies have shown that PBSC can be stored at 4Dg C for two to three days, allowing autologous stem cell transplantation (ASCT) in patients with multiple myeloma receiving high dose melphalan. Data with non-cryopreserved PBSC in patients autografted for lymphoma following longer preconditioning regimens are limited. In addition, there has been no controlled comparison able to possibly detect unforeseen differences. Patients and methods: We compared outcomes of 94 consecutive adult patients with lymphomas (66 with Hodgkin Lymphoma) autografted in our department in Oran (Algeria), using PBSC stored at 4 dg C, from 2009 to 2018 with patients receiving cryopreserved stem cells reported to the EBMT registry. Patient's autografted in Oran were matched with patients receiving cryopreserved PBSC in the registry (4 controls per Oran Patient). Results: Neutrophil engraftment was significantly faster with cryopreserved PBSC (p= 0.003): by day 10, only 17% of patients receiving non-cryopreserved PBSC engrafted versus 48% for cryopreserved PBSC. Likewise, platelet recovery to 20 000/mm3 was significantly faster in patients receiving cryopreserved PBSC (p=0.01). However, all patients in both groups had recovered by day 20. There were no significant differences in Non Relapse Mortality (9% versus 7%; p=0.4), Relapse Incidence (22% versus 32%; p=0.13), Progression Free Survival (70% versus 61%; 0.4) or Overall Survival (85% versus 75%; p=0.3). Conclusion: This analysis suggests that, in patients with lymphomas receiving pretransplant regimens such as the BEAM, PBSC stored at 4dg C for up to six days can be used safely in centers with no cryopreservation facility. The kinetics of recovery of hematopoiesis however did show a significant, albeit small, delay of engraftment for both neutrophils and platelets, which favors the use of cryopreservation if available. Disclosures Blaise: Jazz Pharmaceuticals: Honoraria. Peggs:Autolus: Consultancy. Salles:Karyopharm: Consultancy; F. Hoffman-La Roche Ltd: Consultancy, Honoraria, Other; Bristol Myers Squibb: Consultancy, Other; Celgene: Consultancy, Honoraria, Other: Participation in educational events; Autolus: Consultancy; Abbvie: Consultancy, Honoraria, Other: Participation in educational events; Genmab: Consultancy; Novartis: Consultancy, Honoraria, Other; Kite: Consultancy, Honoraria, Other; Takeda: Consultancy, Honoraria, Other; Debiopharm: Consultancy; Amgen: Honoraria, Other: Participation in educational events; MorphoSys: Consultancy, Honoraria, Other; Gilead: Consultancy, Honoraria, Other: Participation in educational events; Janssen: Consultancy, Honoraria, Other: Participation in educational events; Epizyme: Consultancy. Milpied:Roche: Honoraria, Other: Travel support; Astellas: Honoraria; Sandoz: Honoraria, Other: consultancy or advisory role; Janssen: Honoraria; Gilead Sciences: Other: consultancy or advisory role; Celgene: Other: Travel support.
- Published
- 2020
15. Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT
- Author
-
Burney, Claire, primary, Robinson, Stephen, primary, Boumendil, Ariane, primary, Finel, Hervé, primary, Khvedelidze, Irma, primary, Hunter, Hannah, primary, Poire, Xavier, primary, Lioure, Bruno, primary, Peggs, Karl S, primary, Foà, Robin, primary, Pillai, Srinivas, primary, Van Meerten, Tom, primary, Bargay, Juan Jose, primary, Schmid, Christoph, primary, Vibeke, Vergote, primary, Ganser, Arnold, primary, Castagna, Luca, primary, Mufti, Ghulam J., primary, and Montoto, Silvia, primary
- Published
- 2019
- Full Text
- View/download PDF
16. Outcome of Patients with Hodgkin Lymphoma Treated with Brentuximab Vedotin for Relapse after Autologous Stem Cell Transplant: A Retrospective Analysis of the LWP-EBMT
- Author
-
Chavda, Nikesh Dhiraj, primary, Robinson, Stephen, additional, Boumendil, Ariane, additional, Khvedelidze, Irma, additional, Finel, Hervé, additional, Akhtar, Saad, additional, Rauf, M S, additional, Durakovic, Nadira, additional, Vrhovac, Radovan, additional, Musso, Maurizio, additional, Brice, Pauline, additional, Arat, Mutlu, additional, Blaise, Didier, additional, Collin, Matthew P., additional, Romejko-Jarosinska, Joanna, additional, Stamatoullas, Aspasia, additional, Ozkurt, Zubeyde Nur, additional, Robak, Tadeusz, additional, Wahlin, Björn E, additional, Wilson, Keith, additional, Alma, Eleonora, additional, Pastano, Rocco, additional, Castagna, Luca, additional, Bazarbachi, Ali, additional, Ghesquieres, Hervé, additional, Colita, Andrei, additional, and Montoto, Silvia, additional
- Published
- 2019
- Full Text
- View/download PDF
17. Ibrutinib for Relapsed Mantle Cell Lymphoma after Standard First Line Therapy and ASCT Is Efficacious but Does Not Overcome the Impact of POD24 - a Retrospective Study from the LWP-EBMT
- Author
-
Srinivas Pillai, Christoph Schmid, Luca Castagna, Xavier Poiré, Claire Burney, Irma Khvedelidze, Herve Finel, Robin Foà, Hannah Hunter, Ariane Boumendil, Ghulam J. Mufti, Silvia Montoto, Tom van Meerten, Karl S. Peggs, Vergote Vibeke, Arnold Ganser, Bruno Lioure, J. Bargay, and Stephen D. Robinson
- Subjects
medicine.medical_specialty ,business.industry ,education ,Immunology ,Retrospective cohort study ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Chemotherapy regimen ,chemistry.chemical_compound ,chemistry ,Median follow-up ,Ibrutinib ,Internal medicine ,medicine ,Rituximab ,Mantle cell lymphoma ,business ,health care economics and organizations ,Progressive disease ,medicine.drug ,Cause of death - Abstract
Introduction Standard first line treatment for mantle cell lymphoma (MCL) in fit patients is induction with cytarabine containing chemo-immunotherapy and a consolidative autologous stem cell transplant (ASCT). Responses are excellent but there is a continuous pattern of relapse. Progression within 24 months (POD24) of standard first line therapy including ASCT has been shown to predict poorer outcomes, which may be ameliorated by alloSCT. Ibrutinib, a Bruton's Tyrosine Kinase inhibitor, is an effective therapy for relapsed MCL. However, there is a paucity of published data of ibrutinib's efficacy in patients treated at relapse after standard first line treatment with ASCT and very little regarding the impact of POD24 on outcomes after ibrutinib and outcomes of subsequent alloSCT. Methods This was a retrospective analysis of the EBMT registry. The inclusion criteria were: patients with MCL ≥18 years old, 1st line therapy containing cytarabine and rituximab, ASCT in first CR/PR between 2009 and 2016 and received ibrutinib for 1st relapse after ASCT. POD24 was defined as progressive disease in less than 24 months after ASCT. Results 66 patients met the inclusion criteria (Table 1) relapsing at a median of 25 months (range 15-33) post ASCT. Thirty-two patients progressed in less than 24 months after ASCT. Ibrutinib was started at a median of 30 days after relapse (range 10-54). Overall response rate (ORR) was 74% [32 (48%) achieving CR and 18 (27%) PR]. The median duration of response was 10.1 months (available for 28 patients). There were no significant differences in the duration of response to ibrutinib for patients with POD24 (median: 10.4 months, IQR 4.0-15.4) compared to POD after 24 months or more (POD≥24) [(median 9.8 months, IQR 6.5-20.7) p=0.9]. Relapse after/during ibrutinib occurred in 21 patients (33%) at a median of 12 months (range 1-34). 13 of those patients were on ibrutinib at the time of relapse and the remaining 8 after ibrutinib had been stopped for a SCT or because of toxicity. Ibrutinib therapy continues at last follow-up in 23 (35%) patients. Ibrutinib was stopped for the following reasons: 16 patients subsequent SCT, 13 relapse, 5 toxicity (cytopenia, infection, tachycardia, hepatitis and poor tolerance, 1 case each), 9 other/unknown reasons. Second SCT was undertaken in 23 patients (22 alloSCT, 1 ASCT), 16 of whom were in CR/PR after only ibrutinib at the time of relapse. For alloSCT recipients, the donor was MUD in 11, MSD in 5 and mismatch related in 6. The majority (n=19) had reduced intensity conditioning. 50% of the patients developed acute GvHD and 50% chronic GvHD (3 extensive). With a median follow up of 17 months post alloSCT, 18 (63%) are in remission. There were no significant differences in PFS (p=0.173) or OS (p=0.336) post alloSCT for patients with POD24 and POD≥24. At last follow up (median follow-up of 22 months after starting ibrutinib), 35 (71%) patients were in CR and 4 (8%) in PR. 17 patients have died; the most common reason was MCL (14 patients), 2 deaths were secondary to alloSCT toxicity and in 1 case the cause of death was unknown. 2-year OS after starting ibrutinib was 72% (69% for alloSCT patients) and 2-year PFS 62%. PFS after starting ibrutinib was significantly better for patients with POD≥24 compared to those with POD24 (72% vs. 53% at 2 years post ASCT, p=0.017) and this translated to an OS benefit (80% vs. 68% at 2 years post ASCT, p=0.019) (figures 1 and 2). Conclusion Ibrutinib therapy did not overcome the poor outcome for patients with POD24 after first line therapy and although there was a high ORR to ibrutinib the median duration of response is only 10.1 months. AlloSCT should therefore be undertaken if possible, in our retrospective cohort of patients it appeared to overcome the poor prognosis of POD24 patients. Disclosures Hunter: Jazz pharamceuticals: Honoraria, Other: speaker fees, Meeting attendance support; Novartis: Honoraria, Other: speaker fees; celegene: Other: Meeting attendance support. Peggs:Autolus: Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Speakers Bureau. Foà:Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Abbvie: Consultancy, Speakers Bureau; Abbvie: Consultancy, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celltrion: Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Consultancy, Speakers Bureau; Celltrion: Membership on an entity's Board of Directors or advisory committees. Pillai:Celgene: Honoraria. Mufti:Celgene Corporation: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Cellectis: Membership on an entity's Board of Directors or advisory committees, Research Funding.
- Published
- 2019
18. Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
- Author
-
Martinez, Carmen, primary, Boumendil, Ariane, additional, Romejko-Jarosinska, Joanna, additional, Anagnostopoulos, Achilles, additional, Faber, Edgar, additional, Poire, Xavier, additional, Yakoub-Agha, Ibrahim, additional, Akhtar, Saad, additional, Gurman, Gunhan, additional, Pavone, Vincenzo, additional, Halaburda, Kazimierz, additional, Botelho Sousa, Aida, additional, Ghesquieres, Herv, additional, Finel, Hervé, additional, Khvedelidze, Irma, additional, Montoto, Silvia, additional, and Sureda, Anna, additional
- Published
- 2018
- Full Text
- View/download PDF
19. Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT
- Author
-
Robinson, Stephen, primary, Boumendil, Ariane, additional, Khvedelidze, Irma, additional, Finel, Hervé, additional, Peggs, Karl, additional, Malladi, Ram K, additional, Potter, Victoria, additional, Tsoulkani, Anna, additional, Vandenberghe, Elisabeth, additional, Chalandon, Yves, additional, Finke, Jürgen, additional, Marijt, Erik, additional, Furst, Sabine, additional, Schaap, Michel, additional, Hunter, Hannah, additional, Snowden, John A, additional, Wadehra, Karan, additional, Wittnebel, Sebastian, additional, Beelen, Dietrich W., additional, Fegueux, Nathalie, additional, Kroeger, Nicolaus, additional, Dreger, Peter, additional, and Montoto, Silvia, additional
- Published
- 2018
- Full Text
- View/download PDF
20. Influence of Donor Type, Stem Cell Source and Conditioning Regimen on Transplant Outcomes after Haploidentical Transplant with Post Transplant Cyclophosphamide for Lymphoma: A Report of the EBMT Lymphoma Working Party
- Author
-
Bazarbachi, Ali, primary, Boumendil, Ariane, additional, Finel, Hervé, additional, Castagna, Luca, additional, Dominietto, Alida, additional, Blaise, Didier, additional, Diez-Martin, Jose L., additional, Tischer, Johanna, additional, Gülbas, Zafer, additional, Labussière, Hélène, additional, Lopez Corral, Lucia, additional, Mohty, Mohamad, additional, Koc, Yener, additional, Yakoub-Agha, Ibrahim, additional, Schmid, Christoph, additional, Elcheikh, Jean, additional, Arat, Mutlu, additional, Forcade, Edouard, additional, Dreger, Peter, additional, Rocha, Vanderson G., additional, guiterez Garcia, Gonzalo, additional, Chalandon, Yves, additional, Ferra, Christelle, additional, Orvain, Corentin, additional, Robinson, Stephen, additional, Montoto, Silvia, additional, and Sureda, Anna, additional
- Published
- 2018
- Full Text
- View/download PDF
21. Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study
- Author
-
Robinson, Stephen, primary, Boumendil, Ariane, additional, Finel, Hervé, additional, Khvedelidze, Irma, additional, Kanfer, Edward, additional, Peggs, Karl, additional, Furst, Sabine, additional, Ram, Ron, additional, Marijt, Waf, additional, Vandenberghe, Elisabeth, additional, Afanasiev, Boris, additional, Wulf, Gerald, additional, Chalandon, Yves, additional, Maertens, Johan, additional, Tsoulkani, Anna, additional, Schaap, Michel, additional, Beelen, Dietrich W., additional, Gurman, Gunhan, additional, Finke, Jürgen, additional, Wittnebel, Sebastian, additional, Di Bartolomeo, Paolo, additional, Tischer, Johanna, additional, Corradini, Paolo, additional, Caballero, Dolores, additional, Marzolini, Maria A V, additional, Burney, Claire, additional, La Nasa, Giorgio, additional, Potter, Victoria, additional, Bittenbring, Jörg Thomas, additional, Fegueux, Nathalie, additional, Kroeger, Nicolaus, additional, Schmitz, Norbert, additional, Dreger, Peter, additional, and Montoto, Silvia, additional
- Published
- 2018
- Full Text
- View/download PDF
22. Donor Lymphocyte Infusions for the Treatment of Relapsed Non-Hodgkin Lymphoma Following Allogeneic Stem Cell Transplantation: A LWP-EBMT Study
- Author
-
Ron Ram, Edward Kanfer, Dietrich W. Beelen, Yves Chalandon, Peter Dreger, Norbert Schmitz, Johanna Tischer, Paolo Corradini, Nicolaus Kroeger, Karl S. Peggs, Sabine Furst, Silvia Montoto, Maria A V Marzolini, Jürgen Finke, Claire Burney, Michel Schaap, Gunhan Gurman, Elisabeth Vandenberghe, Paolo Bartolomeo, Dolores Caballero, Boris V. Afanasiev, Irma Khvedelidze, Sebastian Wittnebel, Herve Finel, Nathalie Fegueux, Gerald Wulf, Jörg Thomas Bittenbring, Waf Marijt, Anna Tsoulkani, Johan Maertens, Ariane Boumendil, Stephen D. Robinson, Victoria Potter, and Giorgio La Nasa
- Subjects
medicine.medical_specialty ,business.industry ,Immunology ,Medizin ,Follicular lymphoma ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Transplantation ,Median follow-up ,Internal medicine ,Medicine ,Alemtuzumab ,T-cell lymphoma ,Mantle cell lymphoma ,business ,Diffuse large B-cell lymphoma ,Progressive disease ,medicine.drug - Abstract
Introduction Relapse of non-Hodgkin lymphoma (NHL) following allogeneic stem cell transplantation (alloSCT) is a common occurrence associated with a poor outcome with limited treatment options. Donor lymphocyte infusions (DLI) are commonly employed in this setting in an attempt to exploit the allogeneic graft versus lymphoma (GVL) effect to induce remissions. There is however a paucity of data describing the efficacy of DLIs in inducing remissions in NHL subtypes and the risk of subsequently developing graft versus host disease (GVHD). We report here the largest series of patients with NHL receiving DLI for relapse after alloSCT. Methods Patients relapsing after an alloSCT for NHL and receiving DLI were identified on the EBMT database. Centres were invited to contribute additional data. 118 patients [follicular lymphoma (FL) n=28, diffuse large B cell lymphoma (DLBCL) n=28, T cell lymphoma (TCL) n=52 and mantle cell lymphoma (MCL) n=10] from 39 centres who received DLI as the only treatment for relapse were identified. Patients receiving DLI in combination with other therapy were excluded from this analysis. The median age at alloSCT was 50 (range 18-73) years. There were 81 male and 37 female patients who underwent an alloSCT with reduced intensity (RIC) (n=90) or myeloablative conditioning (MAC) (n=28) at a median of 2.4 (range 0.3-26.3) years from diagnosis. Allogeneic cells were provided from matched sibling (n=63), unrelated (n=47) or mismatched family (n=8) donors and 85 patients received either ATG/ALG or CAMPATH as part of GVHD prophylaxis. The median time from alloSCT to relapse was 3.8 months (range 18 days-67 months). Results Patients received a median of 1 (range 1-19) DLI at a median starting dose of 1.5 x106 CD3/kg (range 0.01-120x106 CD3/kg) at a median of 152 days (range 18-2136) post alloSCT. The median last dose of DLI was 10x106/kg (range 0.1-180x106/kg) given at a median of 353 days (range 41-2725) post alloSCT. The median time from relapse to the first DLI was 35 days (range 0-168). Acute GVHD and chronic GVHD prior to DLI was reported in 29% and 14% of patients, respectively. Of 93 evaluable patients 47 (51%) patients achieved a complete remission, 10 (11%) a partial remission, 13 (14%) stable disease and 23 (25%) had progressive disease following DLI. The median duration of response was 36 months (range 1-168). When analysed according to histology the overall response rate (ORR) (CR+PR) for FL was 84% (CR 68%), DLBCL 41% (32% CR), TCL 54% (46% CR) and MCL 86% (CR 71%). The median duration of responses for FL, DLBCL, TCL and MCL were 30 (range 2-150), 38 (4-76), 37 (range 1-168) and 50 months (13-116) respectively. With a median follow up of 77 months after the 1st DLI 36 (31%) patients remain in complete remission, 29 (25%) without any further therapy. 37 (35%) went on to receive additional antilymphoma therapy after the DLI. Of 17 patients with FL achieving a CR post DLI 12 (71%) remain in remission without further therapy at a median of 78 (9-158) months after DLI. Of 18 patients with TCL that achieved a CR with DLI, 15 (83%) remain in remission without further therapy at a median of 95 (range 42-161) months after DLI. Following the DLI 43 (36%) patients developed aGVHD (6 grade I, 13 grade II, 11 grade III, 9 grade IV, 4 grade unknown) and 33 (28%) developed cGVHD (11 limited, 20 extensive, 2 unknown). Following the first DLI the cumulative incidence of relapse was 31% (CI 22-41) at 4 years and of NRM 28% (CI 20-37). The 4-year PFS after 1st DLI was 39% (CI 30-50) and the OS, 44% (CI 35-54). Conclusions DLI induce significant rates of disease response in patients with NHL relapsing after alloSCT providing clear proof of principle of the allogeneic GVL effect. The rates of response are most impressive in FL and MCL. The majority of patients with TCL and FL that achieve a CR post DLI remain in remission with long term follow up. Acute and chronic GVHD is a significant complication of DLI. Disclosures Robinson: Sandoz: Speakers Bureau; Gilead: Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau. Chalandon:Roche: Membership on an entity's Board of Directors or advisory committees, Other: Travel costs. Beelen:Medac: Consultancy, Other: Travel Support. Finke:Neovii: Consultancy, Honoraria, Other: travel grants, Research Funding; Medac: Consultancy, Honoraria, Other: travel grants, Research Funding; Riemser: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Other: travel grants, Research Funding. Tischer:Jazz Pharmaceuticals: Other: Jazz Advisory Board. Corradini:Amgen: Honoraria, Other: Advisory Board & Lecturer; Novartis: Honoraria, Other: Advisory Board & Lecturer; Abbvie: Honoraria, Other: Advisory Board & Lecturer; Sandoz: Other: Advisory Board; Sanofi: Honoraria, Other: Advisory Board & Lecturer; Gilead: Honoraria, Other: Advisory Board & Lecturer; Takeda: Honoraria, Other: Advisory Board & Lecturer; Roche: Honoraria, Other: Advisory Board & Lecturer; Janssen: Honoraria, Other: Lecturer; Celgene: Honoraria, Other: Advisory Board & Lecturer.
- Published
- 2018
23. Efficacy and Toxicity of Donor Lymphocyte Infusions in the Management of Mixed Donor-Recipient Chimerism Following Allogeneic Stem Cell Transplantation for Lymphoid Malignancies:- a Study of the LWP-EBMT
- Author
-
Elisabeth Vandenberghe, Herve Finel, Sebastian Wittnebel, Anna Tsoulkani, Nicolaus Kroeger, Hannah Hunter, Ariane Boumendil, Silvia Montoto, Dietrich W. Beelen, Sabine Furst, Ram Malladi, Erik W.A. Marijt, Michel Schaap, Yves Chalandon, Peter Dreger, Karan Wadehra, Irma Khvedelidze, John A. Snowden, Karl S. Peggs, Nathalie Fegueux, Jürgen Finke, Stephen D. Robinson, and Victoria Potter
- Subjects
business.industry ,Lymphocyte ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Transplantation ,Haematopoiesis ,Graft-versus-host disease ,medicine.anatomical_structure ,Cancer research ,Medicine ,T-cell lymphoma ,Mantle cell lymphoma ,Stem cell ,business ,Diffuse large B-cell lymphoma - Abstract
Introduction The development of mixed donor recipient (MDR) chimerism is a frequent occurrence following allogeneic transplantation (alloSCT) for lymphoid malignancies. There is evidence that achievement of full donor (FD) lympho-haematopoietic chimerism (LHC) is associated with a lower chance of disease recurrence and consequently donor lymphocyte infusions (DLI) are commonly employed in this setting. There is however a paucity of data describing both the efficacy of DLI in achieving FD LHC and their toxicity in terms of inducing graft versus host disease (GVHD). We therefore undertook a large survey within the EBMT to determine the efficacy and toxicity of DLI when used for MDR LHC. Methods and Patients All centres within the EBMT database that had administered DLI for MDR LHC in patients undergoing an alloSCT for lymphoid malignancies were invited to submit additional data for this study. Data was provided for 135 patients from 36 centres. The median age at diagnosis was 44.6 years (15-64) and the median age at SCT was 47 years (range 19-68). Patients were diagnosed with DLBCL (n=17), follicular NHL (n=45), Hodgkin lymphoma (n=21), mantle cell lymphoma (n=32), T cell lymphoma (n=14) and other lymphoid malignancies (n=6). Prior autologous transplantation had been performed in 45 patients. 122 patients underwent reduced intensity conditioning prior to transplantation from a matched sibling donor (n=90), unrelated donor (n=42) or mismatched family donor (n=3). T cell depletion (TCD) of the graft was performed in 33 cases. Results MDR LHC was demonstrated by analysis of whole blood (WB) in 34 patients and in T cell and myeloid lineages in 101 patients. The median time from alloSCT to the demonstration of MDR LHC was 4.9 months (range 4.6-63) and the median time to the 1st DLI was 7.8 months (range 1-63). Patients received a median of 2 DLI (range 1-20) at a median starting dose of 1x106 CD3/kg recipient (range 0.1-380 x 106/kg). Of the 135 patients receiving DLI 121 were assessable for response with 94 (78%) achieving full donor LHC, 24 (20%) remaining MDR, 2 patients became fully recipient and one patient had a mixed response (FD in T cells but MDR in myeloid lineage). For the patients that received DLI for T cell MDR chimerism (N=71, with 64 assessable for response) 55 (86%) became FD, 8 (12.5%) remained MDR and 1 became fully recipient. For patients that received DLI for myeloid MDR chimerism (with or without MDR chimerism in the T lineage) (N=30, with 29 assessable for response) 17 (59%) converted to full donor in the myeloid lineage, 10 (34%) remained MDR, 1 had a mixed response and 1 became full recipient. If patients required 3 or more DLIs the chance of conversion to FD fell significantly to 55% compared to 89% for those that only received 1 DLI (p Acute GVHD developed in 45 of 134 (34%) evaluable patients after the 1st DLI (grade I in 12, grade II in 12, grade III in 6, grade IV in 8 and grade unknown in 7). Chronic GVHD developed in 36 of 130 (28%) evaluable patients which was extensive in 13 (10%). Acute GVHD (grades II-IV) was seen more commonly after the 1st DLI than after 2 or more DLIs (68% post 1st DLI vs 14% after 2 or more DLIs at 100 days p=0.002) and in patients undergoing unrelated donor transplantation (62% vs 23% at 100 days, p=0.02). Chronic GVHD was more common after DLIs given to patients that had received a TCD graft (39% vs 17% p=0.007). The median follow-up after the 1st DLI was 70 months (range 11-149). Relapse following DLI occurred in 36 (27%) patients which was more common in patients receiving DLI for myeloid MDR chimerism compared to T cell MDR (40% vs 22.5%). Disease relapse occurred in 36 (27%) patients after receiving the first DLI, 11 of whom had achieved full donor FD LHC prior to relapse. In a time-dependent Cox model conversion to FD LHC was not protective against relapse. Conclusions. In this large series of patients with lymphoid malignancies the administration of DLI is an effective strategy for achieving FD chimerism particularly when the MDR chimerism is restricted to the T cell lineage. Development of GVHD is a significant complicating factor particularly in the unrelated donor setting and when the original graft was T cell depleted. Disclosures Robinson: Roche: Consultancy, Honoraria, Speakers Bureau; Gilead: Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria, Speakers Bureau; Sandoz: Speakers Bureau. Chalandon:Roche: Membership on an entity's Board of Directors or advisory committees, Other: Travel costs. Finke:Novartis: Consultancy, Honoraria, Other: travel grants, Research Funding; Medac: Consultancy, Honoraria, Other: travel grants, Research Funding; Neovii: Consultancy, Honoraria, Other: travel grants, Research Funding; Riemser: Consultancy, Honoraria, Research Funding. Beelen:Medac: Consultancy, Other: Travel Support.
- Published
- 2018
24. Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation
- Author
-
Xavier Poiré, Saad Akhtar, Herv Ghesquieres, Herve Finel, Aida Botelho Sousa, Carmen Martinez, Irma Khvedelidze, Joanna Romejko-Jarosinska, Ariane Boumendil, Edgar Faber, Achilles Anagnostopoulos, Vincenzo Pavone, Anna Sureda, Kazimierz Hałaburda, Silvia Montoto, Ibrahim Yakoub-Agha, and Gunhan Gurman
- Subjects
Oncology ,medicine.medical_specialty ,Marrow transplantation ,business.industry ,Registry study ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Lymphoma ,Autologous stem-cell transplantation ,Internal medicine ,medicine ,Refractory Hodgkin Lymphoma ,business - Abstract
Patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) after first autologous stem cell transplantation (ASCT1) may be offered several therapeutic options. New agents such as brentuximab vedotin or checkpoint inhibitors have recently been approved for the treatment of these patients, however, their efficacy to provide long-term control or cure is still unknown. Thus, a significant proportion of patients are still considered candidates for a second hematopoietic stem cell transplantation, usually an allogeneic transplantation. A second ASCT (ASCT2) has historically been considered as an option only in a small group of patients so the published experience is scarce. We retrospectively evaluated the outcome of 56 adult patients (25% female/75% male) with R/R HL registered in the EBMT database who received an ASCT2 between 2005 and 2014. Planned tandem ASCT were excluded. The median age at ASCT2 was 33 years (range, 19-71) and most patients (n=46, 87%) had a Karnofsky performance score ≥80%. Forty (73%) and 9 (16%) patients were in complete remission (CR) and partial remission (PR), respectively, at day 100 after ASCT1. Twenty-six (46%) relapsed within 12 months after ASCT1. Patients received a median of 1 (0-5) treatment lines between ASCT1 and ASCT2. Of note, only 2 patients received brentuximab vedotin after ASCT1 and none of the patients in our series received checkpoint inhibitors as salvage after ASCT1. The median interval from relapse/progression to ASCT2 was 9.7 months (1.7-89.3). At the time of ASCT2, 38 (69%) patients had chemosensitive disease (20 of them CR; and 18 PR). Most patients (n=43, 77%) received BEAM as the conditioning regimen for ASCT1, whereas preparative regimens for ASCT2 were more heterogeneous (BEAM or similar in 27, 48%; CBV or similar in 8, 14%; and others in 21, 37%). The median time to neutrophil (>0.5x109/L) and platelet (>20x109/L) recovery after ASCT2 were 11 (IQR 9-12) and 12 (IQR 10-15) days, respectively. Best response at day 100 following ASCT2 included CR in 29 (52%) patients and PR in 7 (12%); 3 (5%) had stable disease, and 3 (5%) progressed. Twenty-nine (52%) patients are currently alive, with a median follow-up for surviving patients of 73 months (2-153). Causes of death were HL progression (n=21, 79%), ASCT2 toxicity (n=3, 11%), secondary neoplasia (n=1, 3.7%), and unknown (n=2, 7%). The 4-year non-relapse mortality (NRM) was 5% (95% CI 1-14%). The 4-year cumulative incidence of disease progression/relapse was 69% (95% CI 54-80%). The 4-year overall survival (OS) and progression free survival (PFS) were 63% (95% CI 51-77%) and 25% (95% CI 16-41%). In univariate analysis, HL relapse within 12 months of ASCT1 was associated with a worse 4-year OS (44% vs. 79%, p=0.016) and PFS (16% vs. 33%, p=0.033). Chemosensitivity at ASCT2 predicted for better outcomes (4-year OS 78% vs. 30%, p=0.002; PFS 34% vs. 6%, p=0.004). Our series is the largest thus far reported of ASCT2 for patients with R/R HL after ASCT1. NRM is lower than that observed after allogeneic transplantation in this setting; however, relapse remains a major issue, especially for patients who relapse in less than one year after ASCT. For this population, a second ASCT should not be considered, whereas ASCT2 in patients with long response duration after ASCT1 might be appropriate in selected cases. The role of ASCT2 for those patients treated with new drugs such as brentuximab vedotin and checkpoint inhibitors deserves further investigation. Disclosures Martinez: BMS: Research Funding; Takeda: Consultancy. Sureda:BMS: Consultancy, Honoraria; Sanofi: Honoraria; Takeda: Consultancy, Honoraria, Speakers Bureau; Roche: Honoraria; Merck: Consultancy, Honoraria.
- Published
- 2018
25. Influence of Donor Type, Stem Cell Source and Conditioning Regimen on Transplant Outcomes after Haploidentical Transplant with Post Transplant Cyclophosphamide for Lymphoma: A Report of the EBMT Lymphoma Working Party
- Author
-
Christelle Ferra, Gonzalo guiterez Garcia, Ariane Boumendil, Mutlu Arat, Johanna Tischer, Peter Dreger, Yener Koc, Vanderson Rocha, Herve Finel, Didier Blaise, Silvia Montoto, Lucía López Corral, Christoph Schmid, Stephen D. Robinson, Corentin Orvain, Mohamad Mohty, Luca Castagna, Anna Sureda, José Luis Díez-Martín, Jean El-Cheikh, Hélène Labussière, Zafer Gulbas, Ibrahim Yakoub-Agha, Alida Dominietto, Ali Bazarbachi, Yves Chalandon, and Edouard Forcade
- Subjects
Oncology ,medicine.medical_specialty ,Cyclophosphamide ,business.industry ,Immunology ,Follicular lymphoma ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,HLA Mismatch ,Peripheral T-cell lymphoma ,Lymphoma ,Transplantation ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Mantle cell lymphoma ,business ,Diffuse large B-cell lymphoma ,medicine.drug - Abstract
Allogeneic stem cell transplantation (SCT) is potentially curative for patients with lymphoma who progress after autologous SCT. For patients with no HLA identical donor, haploidentical transplant is becoming the major source of alternative donors, particularly with the use of post transplant cyclophosphamide (ptCy). However, there are little data on whether outcomes are affected by the characteristics of the haploidentical donor, the stem cell source or the conditioning. To address this important subject, we identified 474 adult patients (35% females; median age 41 years; range 18-72) with Hodgkin lymphoma (HL-240; 51%), peripheral T cell lymphoma (PTCL-88; 19%), diffuse large B cell lymphoma (DLBCL-77; 16%), mantle cell lymphoma (MCL-40; 8%) or follicular lymphoma (FL-29; 6%), who received a haploidentical SCT (haploSCT) with ptCy between 2010 and 2016 at EBMT participating centers. Patients, donors and transplant characteristics are summarized in Table 1. Median follow-up of alive patients was 32 months (range 3-93). Engraftment by day 100 was successful in 95% of patients. In multivariate Cox analysis (MVA), the use of peripheral blood stem cells (PBSC) positively affected engraftment (HR=1.53; p In conclusion, this is the largest study on the influence of donor characteristics, stem cell source and conditioning in haploSCT with ptCy for lymphoma. These results provide critical information to help selecting the best donor in the setting of haploSCT for lymphoma. Our results indicate that the use of PBSC significantly improves engraftment but increases the risk of acute GVHD. Conditioning only influenced NRM but had no effect on PFS or OS. The use of female donors increases the risk of chronic GVHD. Of note, PFS and OS are mostly influenced by disease characteristics (i.e disease status and lymphoma subtype), whereas, with the exception of CMV compatibility, no other donor characteristics (donor age and gender, relationship of the donor to the recipient, degree of HLA mismatch or ABO incompatibility, prior donor pregnancy) impact on PFS or OS, supporting the use of any haplo-identical family member as a donor. Table. Table. Disclosures Tischer: Jazz Pharmaceuticals: Other: Jazz Advisory Board. Mohty:MaaT Pharma: Consultancy, Honoraria. Chalandon:Roche: Membership on an entity's Board of Directors or advisory committees, Other: Travel costs. Sureda:BMS: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Speakers Bureau; Sanofi: Honoraria; Merck: Consultancy, Honoraria; Roche: Honoraria.
- Published
- 2018
26. Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Kyriakou, Charalampia, primary, Boumendil, Ariane, additional, Finel, Herve, additional, Schmitz, Norbert, additional, Sengeloev, Henrik, additional, Mackinnon, Stephen, additional, Blaise, Didier, additional, Chevallier, Patrice, additional, Browne, Paul, additional, Craddock, Charles, additional, Niederwieser, Dietger W., additional, Schetelig, Johannes, additional, Lenhoff, Stig, additional, Fegueux, Nathalie, additional, Montoto, Silvia, additional, and Dreger, Peter, additional
- Published
- 2016
- Full Text
- View/download PDF
27. Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Akhtar, Saad, primary, Montoto, Silvia, additional, Boumendil, Ariane, additional, Castagna, Luca, additional, Finel, Herve, additional, Masszi, Tamas, additional, Jindra, Pavel, additional, Nemet, Damir, additional, Baurmann, Herrad, additional, Beguin, Yves, additional, Ferrara, Felicetto, additional, Capria, Saveria, additional, Malladi, Ram, additional, Moraleda, Jose M, additional, Salles, Gilles, additional, Bloor, Adrian, additional, Meissner, Julia, additional, Sureda, Anna, additional, and Dreger, Peter, additional
- Published
- 2016
- Full Text
- View/download PDF
28. Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party
- Author
-
Huebel, Kai, primary, Re, Alessandro, additional, Boumendil, Ariane, additional, Finel, Herve, additional, Hentrich, Marcus, additional, Michieli, Mariagrazia, additional, Kanfer, Edward, additional, Diez-Martin, Jose Luis, additional, Balsalobre, Pascual, additional, Vincent, Laure, additional, Schroyens, Wilfried, additional, Ribera Santasusana, Josep Maria, additional, Kröger, Nicolaus, additional, Schiel, Xaver, additional, Thomson, Kirsty J, additional, Sierra, Jorge, additional, Botelho Sousa, Aida, additional, Montoto, Silvia, additional, and Dreger, Peter, additional
- Published
- 2016
- Full Text
- View/download PDF
29. A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma
- Author
-
Liebers, Nora, Finel, Hervé, Edelmann, Dominic, Kobbe, Guido, Bärmann, Ben-Niklas, Serroukh, Yasmina, Blaise, Didier, Beelen, Dietrich W., Solano, Carlos, Itäla-remes, Maija, Broers, Annoek E.C., Choi, Goda, Kroeger, Nicolaus, Byrne, Jenny Louise, Tudesq, Jean-Jacques, Nunes, Ana, Siddiqi, Rubina, Baro, Elande, Zheng, Dan, Kloos, Ioana, Dreger, Peter, Sureda Balari, Anna Maria, Glass, Bertram, and Dietrich, Sascha
- Abstract
Introduction
- Published
- 2023
- Full Text
- View/download PDF
30. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplants for Patients with Hodgkin disease: A Comparative Study of the LWP EBMT
- Author
-
Montoro, Juan, Boumendil, Ariane, Finel, Hervé, Bramanti, Stefania, Castagna, Luca, Blaise, Didier, Dominietto, Alida, Kulagin, Aleksandr, Yakoub-Agha, Ibrahim, Tbakhi, Abdelghani, Solano, Carlos, Giebel, Sebastian, Gulbas, Zafer, Caballero, Dolores, Perez-Simon, Jose A., Diez Martin, Jose Luis, Corradini, Paolo, Koc, Yener, Socié, Gerard, Arat, Mutlu, Jurado, Manuel, Bermudez, Arancha, Labussière-Wallet, Hélène, Villalba, Marta, Ciceri, Fabio, Rovira, Montserrat, Nagler, Arnon, Sureda Balari, Anna Maria, and Glass, Bertram
- Abstract
INTRODUCTION
- Published
- 2023
- Full Text
- View/download PDF
31. Efficacy of CD19-Directed CAR T Cell Therapy in Patients with Primary or Secondary CNS Lymphoma - an Analysis of the EBMT Lymphoma WP and the Gocart Coalition
- Author
-
Ossami Saidy, Anna, Fuhrmann, Stephan, Peczynski, Christophe, Boumendil, Ariane, Michel, Eva, Galimard, Jacques-Emmanuel, Finel, Hervé, Daskalakis, Michael, Novak, Urban, Beauvais, David, Vandenberghe, Peter, Kröger, Nicolaus, Ram, Ron, Finke, Jürgen, Stelljes, Matthias, Wulf, Gerald G., Bethge, Wolfgang Andreas, von Bonin, Malte, Bug, Gesine, Kuhnl, Andrea, Passweg, Jakob, Stoelzel, Friedrich, von Tresckow, Bastian, Sureda Balari, Anna Maria, Dreger, Peter, Schmitz, Norbert, and Glass, Bertram
- Abstract
Introduction: The prognosis of patients (pts) with relapsed or refractory (r/r) large B cell lymphoma (LBCL) and central nervous system (CNS) involvement is dismal. Standard treatment for pts with r/r LBCL are anti-CD19 chimeric antigen receptor T-cells (CART). Several reports with limited numbers of patients suggest that CART might also be an effective treatment for pts with CNS lymphoma. This EBMT registry study aimed at compiling data to investigate the potential of CART in pts with primary (PCNSL) or secondary CNS lymphoma (SCNCL).
- Published
- 2023
- Full Text
- View/download PDF
32. Hematopoietic Stem Cell Transplantation for DLBCL: 55,000 Cases from EBMT As a Comparator for CAR T-Cells
- Author
-
Berning, Philipp, Boumendil, Ariane, Goldstone, Anthony H., Sureda Balari, Anna Maria, Dreger, Peter, Montoto, Silvia, Ngoya, Maud, Finel, Hervé, Chevallier, Patrice, Blaise, Didier, Struessmann, Tim, Carpenter, Ben, Forcade, Edouard, Castilla-Llorente, Cristina, Trněný, Marek, Ghesquieres, Herve, Saveria, Capria, Thieblemont, Catherine, Wolfgang Blau, Igor, Meijer, Ellen, Broers, Annoek E.C., Huynh, Anne, Caillot, Denis, Roesler, Wolf, Nguyen Quoc, Stéphanie, Bittenbring, Jörg, Nagler, Arnon, Glass, Bertram, and Schmitz, Norbert
- Abstract
Introduction:
- Published
- 2023
- Full Text
- View/download PDF
33. Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party
- Author
-
Laure Vincent, Pascual Balsalobre, Josep Maria Ribera Santasusana, José Luis Díez-Martín, Xaver Schiel, Peter Dreger, Marcus Hentrich, Aida Botelho Sousa, Kai Huebel, Nicolaus Kröger, Alessandro Re, Silvia Montoto, Wilfried Schroyens, Kirsty Thomson, Mariagrazia Michieli, Herve Finel, Jorge Sierra, Edward Kanfer, and Ariane Boumendil
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Immunology ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Chemoimmunotherapy ,hemic and lymphatic diseases ,Internal medicine ,Medicine ,Performance status ,business.industry ,Cell Biology ,Hematology ,medicine.disease ,Chemotherapy regimen ,Lymphoma ,Surgery ,Regimen ,030104 developmental biology ,030220 oncology & carcinogenesis ,business ,Diffuse large B-cell lymphoma ,Burkitt's lymphoma ,Plasmablastic lymphoma - Abstract
Introduction: Patients infected with HIV have an increased risk of developing aggressive B-cell non-Hodgkin lymphoma and Hodgkin lymphoma (HL). The continuous development of cART during the last decade has improved the prognosis of HIV-associated lymphoma considerably. However, a significant proportion of these patients will experience lymphoma relapse and may be candidates for autoSCT. The purpose of the present study was to investigate if recent advances in anti-lymphoma therapy and anti-infectious strategies have influenced the outcome of autoSCT for HIV-related lymphoma. Patients and methods: For this retrospective study, all EBMT-registered patients aged 18 years or older with HIV-positive serostatus who were treated with a first autoSCT between 2007 and 2013 were eligible. Baseline patient, disease, and transplant data were collected from MED-A forms. Centers were requested to provide additional HIV and lymphoma treatment and follow-up information. Statistical analysis used log rank test to assess the impact of baseline characteristics on survival endpoints. In multivariate analysis, the relevance of prognostic factors was estimated using Cox regression models. Curves of cumulative incidence of relapse (IR) and non-relapse mortality (NRM) were compared by Gray's test. Results: 138 patients from 25 European centers met the eligibility criteria and had the full data set required for this analysis available. 86% were male, median age was 44 years (range 24-69). Underlying diagnoses were diffuse large B cell lymphoma (DLBCL) in 46%, HL in 21%, Burkitt lymphoma in 14%, plasmablastic lymphoma (PBL) in 10%, and other lymphoma in 9% of the patients. Disease status at autoSCT was complete remission (CR) in 51%, partial remission (PR) in 33%, and less than PR in 16% of the patients, achieved after 1 (28%), 2 (58%), or more than 2 lines of chemotherapy (14%). With HIV load below the threshold of detection in 74% of the patients, the median CD4+ cell count was 187/µl (range 0-800) at transplant. 95% of the patients continued with cART during salvage and high-dose chemotherapy. BEAM was used as high-dose regimen in 77% of the patients. With a median follow-up of 4 years, 2-year NRM, IR, progression-free survival (PFS) and overall survival for the whole series were 9%, 23%, 68% and 70%, respectively. By multivariate analysis, diagnosis DLBCL or PBL (vs HL), increasing number of chemotherapy pretreatment lines, and less than PR at autoSCT were significant predictors of an unfavorable PFS; whilst age, high-dose regimen, performance status, and viral load had no significant impact. 2-year PFS in patients with 1st-line CR, later CR, PR, or less than PR at autoSCT was 91%, 80%, 64%, and 23%, respectively. Conclusions: This series, which is the largest ever on lymphoma transplants in HIV+ patients, suggests that in the cART / chemoimmunotherapy era, the outcome of autoSCT for HIV-related lymphoma is driven by lymphoma-dependent risk factors rather than by characteristics of HIV infection. AutoSCT under ongoing cART therapy remains the treatment of choice for HIV+ patients with PBL or recurrent DLBCL or HL. Disclosures Kröger: Sanofi: Honoraria, Research Funding; Neovii: Honoraria, Research Funding; Riemser: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Montoto:Roche: Honoraria; Gilead: Research Funding. Dreger:Novartis: Consultancy; Gilead: Speakers Bureau; Novartis: Speakers Bureau; Gilead: Consultancy; Janssen: Consultancy; Roche: Consultancy.
- Published
- 2016
34. Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL): High Efficacy of High Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC auto-SCT). A Study of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Adrian Bloor, Pavel Jindra, Herrad Baurmann, Silvia Montoto, Saad Akhtar, Tamas Masszi, Damir Nemet, Gilles Salles, Luca Castagna, Ariane Boumendil, José M. Moraleda, Julia Meissner, Yves Beguin, Anna Sureda, Saveria Capria, Felicetto Ferrara, Herve Finel, Peter Dreger, and Ram Malladi
- Subjects
medicine.medical_specialty ,business.industry ,Incidence (epidemiology) ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Chemotherapy regimen ,Lymphoma ,Log-rank test ,03 medical and health sciences ,High dose chemotherapy ,0302 clinical medicine ,Autologous stem-cell transplantation ,Interquartile range ,030220 oncology & carcinogenesis ,Internal medicine ,medicine ,Rituximab ,business ,030215 immunology ,medicine.drug - Abstract
Background: NLPHL is a relatively uncommon subtype of Hodgkin lymphoma (HL) accounting for about 5-6% of all HL cases. It has unique clinico-pathological, morphologic and immunohistochemical features with CD20-positive "lymphocyte predominant cells". Although long-term survival is better than in classical HL, frequent relapses are common and progression/transformation to aggressive non-Hodgkin lymphoma (NHL) may occur. Whilst HDC auto-SCT is considered as standard of care for relapsed/refractory classical HL, data on HDC auto-SCT in relapsed/refractory NLPHL is sparse. Here, we report a registry study of HDC auto-SCT for NLPHL using the EBMT database, representing the largest sample analyzed to date. Design: Eligible were patients with NLPHL18 years or older who underwent a first auto-SCT between 2003 and 2013, and were registered with the EBMT. Patients with NLPHL transformed to DLBCL were not eligible. The primary objective was 5-year progression-free survival (PFS). Baseline patient, disease and transplant data were collected from EBMT MED-A standard forms. Centers with potentially eligible patients were contacted to provide additional treatment and follow-up details with a copy of written diagnostic report for central review. Statistical analysis was descriptive and employed log rank comparisons for univariate assessment of the impact of baseline characteristics on survival endpoints. Results: We identified 92 patients who met the inclusion criteria with full data including a written diagnostic pathology report available. Of these, 36 patients were excluded after histopathology report review (17 classical HL, 2 NHL, 17 no sufficient information). The final sample comprised 56 patients. There was a predominance of male patients with a male:female ratio of 88%:12%. Median age was 36 (interquartile range (IQR) 29-50) years. Most patients (65%) had advanced stage (III-IV) at diagnosis and one third had B-symptoms. Prior to HDC auto-SCT, 71% patients had 2, 20% had 3, and the remainder had more than 3 lines of treatment (median: 2 lines). Rituximab was used in 62% of patients. The median time from diagnosis to HDC auto-SCT was 21 (IQR 14-51) months. Disease status prior to HDC auto-SCT was complete remission (CR) in 54% and partial remission (PR) in 43%. Most commonly used HDC was BEAM (84% patients), with additional rituximab in 13%. With a median follow-up of survivors of 5 (IQR 3.6-6.6) years, 5-year PFS and overall survival were 67% (95%CI 55-82) and 86% (95%CI 77%-96%), respectively. The 5-year incidence of relapse was 32% (95%CI 20-46). There were no transplant-related deaths. Univariate comparisons considering age, time from diagnosis to transplant, number of pre-treatment lines and rituximab use during induction, salvage and/or HDT failed to identify significant predictors of PFS or OS endpoints. Conclusions: This study, the largest reported thus far on HDC auto-SCT in NLPHL, shows that two thirds of patients remain free of disease 5 years after HDC auto-SCT. In contrast with the usual characteristics of patients with NLPHL, those included in this series had high-risk disease with B-symptoms and advanced stage at diagnosis, and half the patients had HDC auto-SCT less than 2 years after diagnosis. This study demonstrates that patients with NLPHL and adverse features can benefit from HDC auto SCT at relapse. Figure. Figure. Disclosures Montoto: Roche: Honoraria; Gilead: Research Funding. Masszi:Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees. Moraleda:Pfizer: Research Funding. Bloor:Janssen: Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GSK: Consultancy, Speakers Bureau; Gilead: Honoraria; Abbvie: Membership on an entity's Board of Directors or advisory committees. Meissner:Amgen: Other: Travel Support; Takeda: Other: Travel Support; Celgene: Other: Travel Support; Teva: Other: Travel Support. Dreger:Novartis: Speakers Bureau; Gilead: Consultancy; Gilead: Speakers Bureau; Novartis: Consultancy; Janssen: Consultancy; Roche: Consultancy.
- Published
- 2016
35. Long-Term Outcome of Allogeneic Stem Cell Transplantation (allo-SCT) in Patients with Waldenstrom Macroglobulinemia (WM)-a Retrospective Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Stig Lenhoff, Nathalie Fegueux, Patrice Chevallier, Ariane Boumendil, Charalampia Kyriakou, Dietger Niederwieser, Peter Dreger, Silvia Montoto, Paul Browne, Johannes Schetelig, Didier Blaise, Herve Finel, Charles Craddock, Norbert Schmitz, Stephen Mackinnon, and Henrik Sengeloev
- Subjects
medicine.medical_specialty ,Performance status ,business.industry ,Immunology ,Waldenstrom macroglobulinemia ,Retrospective cohort study ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Surgery ,Log-rank test ,Transplantation ,hemic and lymphatic diseases ,Internal medicine ,Medicine ,Cumulative incidence ,Rituximab ,Risk factor ,business ,medicine.drug - Abstract
WM is an indolent lymphoma that has benefited from the introduction of novel agents with the achievement of higher response rates. However, WM remains incurable with conventional treatment. In addition, patients with high risk disease have either transient short lived responses or are refractory to conventional treatments. Although international treatment recommendations suggest considering allo-SCT in late relapses or in refractory younger patients, the place and timing of allo-SCT in the treatment algorithm of WM remains unclear. The aim of the present study was to analyse the long-term outcome of allo-SCT in WM. Patients and methods: Eligible for this retrospective study were patients aged 18 years or older who had a first reduced intensity (RIC) or myeloablative (MAC) conditioning allo-SCT (10/10 matched donor, sibling or unrelated) for WM between 2001 and 2013 and were registered with the EBMT. Baseline patient, disease and transplant data were collected from MED-A forms. Centers were requested to provide additional diagnostic, treatment and follow-up information. Statistical analysis used log rank test to assess the impact of baseline characteristics on survival endpoints. In multivariate analysis, prognostic factors for survival were estimated using Cox regression models and for relapse incidence (IR) and non-relapse mortality (NRM) by Fine and Gray models. Results: 260 patients (72% male) fulfilling the inclusion criteria of this study were identified in the database. The median age was 52 (range 19-72) years. Disease status at allo-SCT was sensitive in 78% and refractory in 22% of the patients. Conditioning was reduced-intensity (RIC) in 66%, with PBSC (92%) being the predominant stem cell source (bone marrow 7%, cord blood 1%). Patients receiving RIC were significantly older and had a longer interval between diagnosis and transplant but were otherwise comparable to patients with myeloablative conditioning (MAC). Donors were related in 65% and unrelated in 35% of the transplants. The median number of treatment lines prior to alloSCT was 3. Pretreatment details were available for 118 patients. Of these, first-line treatment was alkylator-based in 80%, purine analogue (PA)-based in 17%, and contained rituximab in 23%; for 2nd-line treatment, these figures were 50%, 36%, and 34%; and for 3rd-line treatment 41%, 32%, and 44%. Less than 10% of the patients had received bortezomib or imide-based regimens in any pretreatment line. At 100 days the cumulative incidence of acute graft versus host disease (aGVHD) grade I-II was 35%, and grade III-IV was 12%. At 2 years the cumulative incidence of chronic GVHD (cGVHD) was 41%. The development of cGVHD did not significantly impact on any outcome on a landmark analysis. After a median follow-up for living patients of 57 months (IQR 31-97), 5-year NRM, IR, progression-free survival (PFS) and overall survival (OS) were 29%, 24%, 47% and 55%. Risk factor analyses considering age, sex, performance status (PS), disease status, pretreatment lines, rituximab exposure, year of transplant, donor, and conditioning identified PS for NRM, disease status for IR, and PS and MAC for OS as significant predictors of an adverse outcome after multivariable adjustment. Although RIC patients tended to have a lower NRM and a better PFS than MAC patients, this was not statistically significant, suggesting that RIC patients had a better survival after relapse. 45 patients were treated with donor lymphocyte infusions (DLI) and results of DLI were reported in 22 patients. Of these, a response was observed in 60%, which was complete in 55%. Conclusions: This large study demonstrates that allo-SCT can effectively induce long-term disease control in heavily pre-treated patients with WM, suggesting that graft-versus-lymphoma effects are active and stable in WM. Accordingly, DLI seems to be a promising treatment option in case of post-transplant disease recurrence. Additional studies are needed to elaborate the place of allo-SCT in the treatment algorithm of WM in the era of novel agents. Disclosures No relevant conflicts of interest to declare.
- Published
- 2016
36. Autologous stem cell transplantation for enteropathy-associated T-cell lymphoma: a retrospective study by the EBMT
- Author
-
Jantunen, Esa, Boumendil, Ariane, Finel, Herve, Luan, Jian-Jian, Johnson, Peter, Rambaldi, Alessandro, Haynes, Andrew, Duchosal, Michel A., Bethge, Wolfgang, Biron, Pierre, Carlson, Kristina, Craddock, Charles, Rudin, Claudius, Finke, Jurgen, Salles, Gilles, Kroschinsky, Frank, Sureda, Anna, and Dreger, Peter
- Published
- 2013
- Full Text
- View/download PDF
37. Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)
- Author
-
Martinez, Carmen, primary, Gayoso, Jorge, additional, Canals, Carmen, additional, Finel, Herve, additional, Bacigalupo, Andrea, additional, Peggs, Karl, additional, Milpied, Noel, additional, Ciceri, Fabio, additional, Socie, Gerard, additional, Corradini, Paolo, additional, Robinson, Stephen, additional, Velardi, Andrea, additional, Fegueux, Nathalie, additional, Gutierrez, Gonzalo, additional, Mackinnon, Stephen, additional, Potter, Michael, additional, Afanasiev, Boris, additional, Sierra, Jorge, additional, Malladi, Ram, additional, Sanz, Miguel A., additional, Russell, Nigel H., additional, Arcese, William, additional, Rocha, Vanderson, additional, Dreger, Peter, additional, and Sureda, Anna, additional
- Published
- 2015
- Full Text
- View/download PDF
38. Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience
- Author
-
Duarte, Rafael F., primary, Boumendil, Ariane, additional, Onida, Francesco, additional, Finel, Herve, additional, Gabriel, Ian H, additional, Arcese, William, additional, Browne, Paul, additional, Beelen, Dietrich W., additional, Kobbe, Guido, additional, Veelken, Joan H, additional, Arranz, Reyes, additional, Greinix, Hildegard T., additional, Lenhoff, Stig, additional, Poiré, Xavier, additional, Ribera, Josep, additional, Thompson, Jacqueline, additional, Zuckerman, Tzila, additional, Mufti, Ghulam J., additional, Cortelezzi, Agostino, additional, Olavarria, Eduardo, additional, Sureda, Anna, additional, and Dreger, Peter, additional
- Published
- 2015
- Full Text
- View/download PDF
39. Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)
- Author
-
Sureda, Anna, primary, Zhang, Mei-Jie, additional, Dreger, Peter, additional, Carreras, Jeanette, additional, Fenske, Timothy S., additional, Finel, Herve, additional, Schouten, Harry C., additional, Montoto, Silvia, additional, Robinson, Stephen, additional, Smith, Sonali M., additional, Boumendil, Ariane, additional, Hamadani, Mehdi, additional, and Pasquini, Marcelo C., additional
- Published
- 2015
- Full Text
- View/download PDF
40. Allogeneic Hematopoietic Cell Transplantation (HCT) for Advanced Mycosis Fungoides and Sezary Syndrome (MF/SS): Impact of Increasing the Use of Unrelated Donors (UD) - the EBMT Lymphoma Working Party Experience
- Author
-
Jacqueline Thompson, Herve Finel, Agostino Cortelezzi, William Arcese, Ghulam J. Mufti, Xavier Poiré, Joan Hendrik Veelken, Guido Kobbe, Paul Browne, Anna Sureda, Ian H Gabriel, Reyes Arranz, Francesco Onida, T. Zuckerman, Josep M. Ribera, Eduardo Olavarria, Dietrich W. Beelen, Rafael F. Duarte, Ariane Boumendil, Peter Dreger, Stig Lenhoff, and Hildegard T. Greinix
- Subjects
medicine.medical_specialty ,Univariate analysis ,business.industry ,Incidence (epidemiology) ,Mortality rate ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,Biochemistry ,Surgery ,Transplantation ,Median follow-up ,Internal medicine ,Cohort ,Medicine ,Cumulative incidence ,business - Abstract
Introduction: The EBMT Lymphoma Working Party has previously reported on the long-term outcome of allogeneic HCT for patients with advanced MF/SS [J Clin Oncol 2014; 32: 3347-8 ]. Among a number of disease and transplant factors influencing patient outcome, the use of UD showed to be the strongest independent factor influencing overall survival (OS). The main shortcoming of the original reports was a limited number of 60 cases in the series, of which only 15 received allogeneic HCT from UD. As UD have been increasingly used during recent years, we sought to extend our previous analysis (1997-2007) to include patients with MF/SS allografted between 2008-2011. Patient and Methods: Endpoints were OS, progression-free survival (PFS), non-relapse mortality (NRM) and incidence of disease relapse/progression (DRP). Eligible were patients >= 18 years who were registered with the EBMT and had received an allogeneic HCT for MF/SS between 1997-2011. Centers with eligible patients were contacted to provide additional treatment and follow-up information including a written diagnostic report. Data were collected from the EBMT Registry (closed in July 2014), and endpoints were defined and analyses performed according to EBMT statistical guidelines (www.ebmt.org). Results: Eligible for final analysis were a total of 113 patients, including our original 60 cases (1997-2007) and 53 new cases (2008-2011): 71 men and 42 women, median age at HCT 48 years (21-72), 77 MF (68%) and 36 SS (32%), with 7 EORTC/ISCL stage IIB, 17 stage III, 46 stage IV-A and 26 stage IV-B (17 missing). Demographics of both time periods were comparable, except for a marked increase in the use of UD (15/60, 25% vs 29/53, 55%; p=0.001) and a reduction in the use of TBI for conditioning (30/60, 50% vs 15/53, 28%; p=0.031) in recent years. At HCT, 52 patients (46%) were refractory or in relapse/progression and 61 (54%) in complete or partial remission. Eighty-six patients (76%) received reduced-intensity (RIC) and 27 (24%) myeloablative (MAC) conditioning regimens, including TBI in 45 cases (40%). With a median follow up in survivors of 72 months (IQR: 39-97), allogeneic HCT for MF/SS offers an estimated OS of 56% at 1 year, 44% at 3 years and 38% at 5 years, and PFS of 34% at 1 year, 28% at 3 years and 25% at 5 years. NRM was 26% at 1 year and 28% at 3 years and thereafter. DRP was the main cause of treatment failure, with a probability of 40% at 1 year, 44% at 3 years and 47% at 5 years, and a mortality rate after DRP of 70% (35/50). It is worth noting that 15 patients (30%) remain alive at last follow up despite DRP, suggesting that some of these patients can be successfully rescued with donor lymphocyte infusions and other therapeutic interventions. The cumulative incidence of acute GVHD was 47% at day 100, and chronic GVHD 35% at 1 year, 45% at 3 years and 48% at 5 years. Interestingly, the univariate analysis showed a statistical trend towards a poorer OS in the cohort of new cases registered from 2008 (p=0.106). However, transplant period had no significant impact when included as a covariate in multivariate analysis, and appears to associate with the higher percentage of UD transplants in the new cohort. The use UD remained the main negative independent factor for OS (HR: 0.490; 95CI: 0.283-0.848; p=0.011) and PFS (HR: 0.468; 95CI: 0.259-0.843; p=0.011) in the multivariate models unstratified and stratified by inclusion period. The use of TBI in conditioning appears to have an independent effect to reduce the risk of DRP in the multivariate analysis (HR: 0.427; 95CI: 0.199-0.917; p=0.029), but does not translate into OS or PFS. Conclusions: This extended series confirms the existence of a clinically relevant graft-versus-lymphoma effect in MF/SS, permitting long-term disease control in a substantial proportion of high-risk patients. Follow-up studies need to address the still significant adverse effect of UD and the role of TBI conditioning in order to improve HCT results in these otherwise fatal disorders. Disclosures Mufti: Celgene Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding. Sureda:Takeda: Consultancy, Honoraria, Speakers Bureau.
- Published
- 2015
41. Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR)
- Author
-
Herve Finel, Mehdi Hamadani, Sonali M. Smith, Stephen D. Robinson, Peter Dreger, Harry C. Schouten, Timothy S. Fenske, Jeanette Carreras, Mei-Jie Zhang, Marcelo C. Pasquini, Anna Sureda, Silvia Montoto, and Ariane Boumendil
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Immunology ,Follicular lymphoma ,Cell Biology ,Hematology ,Hematopoietic stem cell transplantation ,medicine.disease ,Biochemistry ,Surgery ,Lymphoma ,Transplantation ,Graft-versus-host disease ,Autologous stem-cell transplantation ,Chemoimmunotherapy ,Internal medicine ,medicine ,Alemtuzumab ,business ,medicine.drug - Abstract
Introduction. The definitive management of R/R FL remains controversial due to various treatment options, including chemoimmunotherapy, pathway inhibitors, and autologous stem cell transplantation (auto-SCT). These options can provide prolonged progression-free survival (PFS). Allogeneic hematopoietic stem cell transplantation (allo-SCT) remains the sole curative therapy for FL. Herein, we report the long term outcome of the largest sample of allo-SCT for FL ever studied as well as the identification of patient and disease related factors that were significantly associated with treatment failure. Patients. Eligible were adult patients with R/R FL having received a first allo-SCT between 2001 and 2011 from an HLA identical sibling donor (SIB) or a well-matched unrelated donor (MUD). Patients with transformed lymphoma were excluded from the analysis as well as planned second transplants, allotransplants from cord blood, mismatched donors, and transplants with ex vivo T cell depletion (TCD). Results. 1567 patients met the eligibility criteria (EBMT, n = 1115; CIBMTR, n = 452). Demographics separated by data source demonstrate some differences in transplant practices between the two regions. The CIBMTR cohort had a higher proportion of MUD recipients [167 (37%) vs 252 (23%), p < 0.001], more cases with chemoresistant disease [113 (25%) vs 145 (13%), p < 0.001], less patients having received a prior auto-SCT [53 (12%) vs 403 (36%), p < 0.001], more use of myeloablative conditioning (MAC) (145 (32%) vs 220 (20%), p < 0.001) and less use of alemtuzumab in-vivo TCD [29 (6%) vs 201 (18%), p < 0.001] compared to the EBMT cohort. Median (range) follow up of survivors in months was 58 (3 - 130) and 54 (3 - 160) for CIBMTR and EBMT patients, respectively. Cumulative incidence of acute (grades II-IV) graft versus host disease (GVHD) was 20% (18-22) at 100 days and of chronic GVHD 45% (42-48) and 55% (52-58) at 1 and 3 years, respectively for the whole series; this risk was slightly but significantly reduced in the EBMT cohort. All major outcomes [non-relapse mortality (NRM), relapse/progression (R/P), overall survival (OS) and PFS] were comparable between the CIBMTR and EBMT samples (Table 1). Table 1. Outcomes CIBMTR EBMT p-value NRMN@ 1 y@ 3 y@ 5 y 45021 (17-25)27 (23-32)31 (26-35) 108819 (16-21)24 (21-27)28 (25-31) 0.3630.1720.114 R/PN@ 1 y@ 3 y@ 5 y 45013 (10-16)16 (13-20)17 (13-21) 108813 (11-15)18 (15-20)21 (18-23) 0.8740.4800.114 PFSN@ 1 y@ 3 y@ 5 y 45066 (62-71)56 (52-61)52 (47-57) 108869 (66-72)58 (55-61)52 (48-55) 0.3750.4950.792 OSN@ 1 y@3 y@ 5 y 45274 (70-78)65 (60-69)61 (56-65) 110475 (72-78)67 (64-70)62 (59-65) 0.5890.4550.695 Multivariate analysis indicated that NRM was significantly affected by age (HR 1.04, 1.02-1.05, p < 0.0001), chemoresistant disease (HR 1.61, 1.28-2.03, p < 0.0001), >= 5 lines of prior CT (vs 3-4) (HR 1.62, 1.20-2.19, p=0.0015) and Karnofsky performance score (KPS) < 80 (HR 2.05 (1.32-3.19, p=0.0014); R/P was significantly affected by grade 3 histology (HR 1.63, 1.16-2.26, p=0.0049) and chemoresistant disease (HR 1.46 (1.07-1.97), p=0.0156); PFS by grade 3 histology (HR 1.42, 1.15-1.76, p=0.0012), chemoresistant disease (HR 1.54, 1.28-1.86, p= 5 lines of prior CT (vs 3-4) (HR 1.45, 1.13-1.85, p=0.0031), MAC (HR 1.36, 1.14-1.63, p=0.0008) and KPS < 80 (HR 1.78, 1.23-2.58, p =0.0022) and OS by age (HR 1.03, 1.02-1.04, p= 5 lines of prior CT (vs 3-4) (HR 1.63, 1.25-2.13, p=0.0003), MAC (HR 1.42, 1.16-1.73, p=0.0006) and KPS < 80 (HR 2.23, 1.52-3.25, p Conclusions. This study represents an example of a fruitful cooperation between two important scientific transplant societies, the EBMT and CIBMTR. Despite significant differences in patient characteristics and transplant strategies between these 2 hitherto largest samples on allo-SCT for R/R FL, long-term disease control was similar and remarkably good with an R/P risk of about only 20% at 5 years. Chemoresistant disease, higher age, multiple pretreatment lines, poor KPS, and MAC all were predictors for an adverse outcome, whereas MUD, TCD, and prior auto-SCT had no impact on any survival endpoint. Disclosures Sureda: Takeda: Consultancy, Honoraria, Speakers Bureau. Fenske:Celgene: Honoraria; Millennium/Takeda: Research Funding; Pharmacyclics: Honoraria; Seattle Genetics: Honoraria. Smith:Celgene: Consultancy; Pharmacyclics: Consultancy.
- Published
- 2015
42. Alternative Donors (Umbilical Cord Blood and Haploidentical Donors) for Allogeneic Stem Cell Transplantation in Relapsed / Refractory Hodgkin Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party and the Spanish Group of Stem Cell Transplantation (GETH)
- Author
-
Stephen Mackinnon, Carmen Martínez, Anna Sureda, Noel Milpied, Carmen Canals, Karl S. Peggs, Boris V. Afanasiev, Nathalie Fegueux, Jorge Gayoso, Paolo Corradini, Fabio Ciceri, Stephen D. Robinson, Jorge Sierra, Ram Malladi, Peter Dreger, Nigel H. Russell, William Arcese, Andrea Bacigalupo, Michael Potter, Gonzalo Gutierrez, Miguel A. Sanz, Herve Finel, Gérard Socié, Vanderson Rocha, and Andrea Velardi
- Subjects
Oncology ,medicine.medical_specialty ,Hematology ,Performance status ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,Immunology ,Cell Biology ,Hematopoietic stem cell transplantation ,medicine.disease ,Biochemistry ,Umbilical cord ,Lymphoma ,Surgery ,Transplantation ,medicine.anatomical_structure ,Internal medicine ,Medicine ,Bone marrow ,business ,medicine.drug - Abstract
Introduction: Allogeneic hematopoietic stem cell transplantation (alloHSCT) is currently considered the standard of care for those patients with HL that relapse after autologous HSCT. Several studies have shown that fit patients with chemosensitive disease can benefit from alloHSCT using and identical sibling (SIB) or matched-unrelated (MUD) donors. Recently, encouraging results have been obtained using haploidentical donors (HAPLO) and post-transplantation cyclophosphamide (ptCY) as graft-versus-host disease prophylaxis (GVHD). Because information regarding the results of alloHSCT using alternative donors is still scarce, we aimed to compare outcome of umbilical cord blood (UCB) and HAPLO transplants with conventional SIB and MUD for HL. Patients and methods: Information of patients older than 17y with HL who received an alloHSCT from a SIB, MUD (8/8 antigen matched), UCB or a ptCY-based HAPLO between 2010-2013 was downloaded from the EBMT and GETH databases. Results: 773 patients with HL were identified meeting the inclusion criteria. 339 received a transplant from a SIB donor, 276 from a MUD, 101 from HAPLO, and 47 from UCB. A significant higher number of patients treated with alloHSCT from UCB and HAPLO donors received reduced intensity (RIC) regimens in comparison to SIB and MUD (76% and 88% vs. 69% and 69%, respectively, p=0.001). Bone marrow was more frequently used as source of stem cells in the HAPLO group in relation to SIB and MUD (61% vs 10% and 11%, respectively, p=0.001), Other variables such as sex, age, performance status, chemorefractory disease, and previous autologous SCT were balanced. Median follow-up after alloHSCT for all patients was 12 months (1-60). The 1-year probabilities of overall survival (OS) and progression-free survival (PFS) were 80% and 49% after SIB transplant, 69% and 54% after MUD, 65% and 40% after UCB, and 73% and 56% after HAPLO, respectively. The 1-year probabilities of non-relapse mortality (NRM) and relapse rate (RR) were 12% and 38% after SIB, 21% and 25% after MUD, 20% and 40% after UCB, and 18% and 27% after HAPLO. Multivariate analysis showed that, in comparison with standard SIB alloHSCT, UCB was associated with a trend to a higher NRM (p=0.08) and RR (p=0.06), leading to a significant lower OS and PFS (p=0.009, HR 2.1, 95% CI 1.2-3.6; p=0.02, HR 1.6, 95% CI 1.1-2.3; respectively). NRM was also significantly higher after MUD (p=0.004, HR 1.8, 95% CI 1.2-2.6), but in contrast, RR was lower (p=0.003 HR 0.6, 95%CI 0.5-0.9) with a lower OS (p=0.002, HR 1.6, 95% CI 1.2-2.1) and no significant differences in PFS. No significant differences were observed between HAPLO and SIB in NRM, RR, PFS and OS. Conclusions: This registry study suggests that in adults with advanced HL, the outcome of pt-CY-based HAPLO HSCT may be comparable to that of conventional SIB alloHSCT and MUD across multiple centers and conditioning regimens. These findings need to be corroborated by longer follow-up. Figure 1. Figure 1. Disclosures Peggs: Autolus: Consultancy, Equity Ownership; Cellectis: Research Funding. Milpied:Celgene: Honoraria, Research Funding. Afanasiev:CELLTRION, Inc.: Research Funding. Russell:Therakos: Other: shares. Sureda:Takeda: Consultancy, Honoraria, Speakers Bureau.
- Published
- 2015
43. Management and Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsed after Autologous Hemopoietic Stem Cell Transplantation (auto-HSCT): A Retrospective Analysis of the Lymphoma Working Party (LWP) of the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Gonzalez-Barca, Eva, Boumendil, Ariane, Blaise, Didier, Trněný, Marek, Masszi, Tamas, Finel, Hervé, Michieli, Mariagrazia, Bittenbring, Jörg Thomas, Gritti, Giuseppe, Snowden, John A., Bishton, Mark, Bruno, Benedetto, González de Villambrosia, Sonia, Janikova, Andrea, Leleu, Xavier, Anagnostopoulos, Achilles, Poire, Xavier, Crysandt, Martina, Nur Özkurt, Zübeyde, Vandenberghe, Elisabeth, Itälä-Remes, Maija, Cahn, Jean-Yves, Jantunen, Esa, Schroyens, Wilfried, Maertens, Johan, Esquirol, Albert, Dreger, Peter, Montoto, Silvia, and Sureda, Anna
- Published
- 2017
- Full Text
- View/download PDF
44. Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom’s Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party
- Author
-
Kyriakou, Charalampia, primary, Boumendil, Ariane, additional, Finel, Herve, additional, Vernant, Jean-Paul, additional, Cornelissen, Jan J., additional, Thieblemont, Catherine, additional, Chevallier, Patrice, additional, Hamladji, Rose-Marie, additional, Mufti, Ghulam J, additional, Mazza, Patrizio, additional, Zachee, Pierre, additional, Niederwieser, Dietger, additional, Sureda, Anna, additional, Montoto, Silvia, additional, and Dreger, Peter, additional
- Published
- 2014
- Full Text
- View/download PDF
45. High Dose Therapy and Autologous Stem Cell Transplantation in Marginal Zone Lymphoma : An EBMT-FIL-Gimeto Retrospective Study
- Author
-
Avivi, Irit, primary, Arcaini, Luca, additional, Ferretti, Virginia, additional, Boumendil, Ariane, additional, Finel, Herve, additional, Pascutto, Cristiana, additional, Milone, Giuseppe, additional, Zaja, Francesco, additional, Liliana, Devizzi, additional, Musso, Maurizio, additional, Didier, Blaise, additional, Salles, Gilles, additional, Wattad, Mohammed, additional, Nicolas-Virelizier, Emmanuelle, additional, Gramatzki, Martin, additional, Bourhis, Jean-Henri, additional, Caillot, Denis, additional, Haenel, Shannon, additional, Haenel, Anette, additional, Held, Gerhard, additional, Thieblemont, Catherine, additional, Jindra, Pavel, additional, Pohlreich, David, additional, Guilhot, François, additional, Bornhaeuser, Martin, additional, Ljungman, Per T., additional, Scheid, Christof, additional, Ifrah, Norbert, additional, Berthou, Christian, additional, Dreger, Peter, additional, Montoto, Silvia, additional, and Conconi, Annarita, additional
- Published
- 2014
- Full Text
- View/download PDF
46. Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin’s Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
- Author
-
Genadieva Stavrik, Sonja G, primary, Boumendil, Ariane, additional, Thomson, Kirsty, additional, Briones, Javier, additional, Corradini, Paolo, additional, Bacigalupo, Andrea, additional, Socie, Gerard, additional, Bandini, Guiseppe, additional, Finel, Herve, additional, Velardi, Andrea, additional, Potter, Michael, additional, Benedetto, Bruno, additional, Castagna, Luca, additional, Craddock, Charles, additional, Russell, Nigel, additional, Dreger, Peter, additional, and Anna, Sureda, additional
- Published
- 2014
- Full Text
- View/download PDF
47. Autologous Stem Cell Transplantation for Primary Mediastinal B Cell Lymphoma in the Rituximab Era: A Retrospective Study By the EBMT Lymphoma Working Party
- Author
-
Avivi, Irit, primary, Boumendil, Ariane, additional, Hervé Finel, Hervé, additional, Nagler, Arnon, additional, Bothello, Aïda Sousa, additional, Santasusana, Josep Maria Ribera, additional, Vandenberghe, Elisabeth A., additional, Afanasyev, Boris, additional, Bordessoule, Dominique, additional, Moraleda, José Maria, additional, Conde, Eulogio, additional, Pohlreich, David, additional, and Dreger, Peter, additional
- Published
- 2014
- Full Text
- View/download PDF
48. Non Interventional Prospective Clinical Study on Peripheral Blood Stem Cell Mobilization in Patients with Relapsed Lymphomas
- Author
-
van Gorkom, Gwendolyn, primary, Finel, Herve, additional, Giebel, Sebastian, additional, Pohlreich, David, additional, Shimoni, Avichai, additional, Ringhoffer, Mark, additional, Sucak, Gulsan Ayhan, additional, Schaap, Nicolaas PM, additional, Dreger, Peter, additional, Sureda, Anna, additional, and Schouten, Harry C, additional
- Published
- 2014
- Full Text
- View/download PDF
49. Haplotransplants Versus Other Alternative Donors for Allogeneic Stem Cell Transplantation in Non Hodgkin Lymphoma (NHL): A Retrospective Analysis of the EBMT Lymphoma Working Party
- Author
-
Dietrich, Sascha, primary, Finel, Herve, additional, Martinez, Carmen, additional, Tischer, Johanna, additional, Blaise, Didier, additional, Chevallier, Patrice, additional, Castagna, Luca, additional, Milpied, Noel, additional, Bacigalupo, Andrea, additional, Corradini, Paolo, additional, Mohty, Mohamad, additional, Sanz, Miguel A., additional, Velardi, Andrea, additional, Hausmann, Andreas, additional, Montoto, Silvia, additional, Hermine, Olivier, additional, Schmitz, Norbert, additional, Schouten, Harry C, additional, Sureda, Anna, additional, Tanase, Alina, additional, Robinson, Stephen, additional, and Dreger, Peter, additional
- Published
- 2014
- Full Text
- View/download PDF
50. Autologous Stem Cell Transplantation (ASCT) for the Treatment of Patients with Waldenstrom’s Macroglobulinemia / Lymphoplasmacytic Lymphoma (WM/LPL). a Risk Factor Analysis By the European Society for Blood and Marrow Transplantation (EBMT) Lymphoma Working Party
- Author
-
Patrizio Mazza, Anna Sureda, Pierre Zachee, Charalampia Kyriakou, Herve Finel, Patrice Chevallier, Peter Dreger, Silvia Montoto, Dietger Niederwieser, Jan J. Cornelissen, Ariane Boumendil, Jean-Paul Vernant, Catherine Thieblemont, Ghulam J. Mufti, and Rose-Marie Hamladji
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Immunology ,Retrospective cohort study ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Log-rank test ,Transplantation ,Autologous stem-cell transplantation ,Interquartile range ,Internal medicine ,medicine ,Rituximab ,Risk factor ,business ,Progressive disease ,medicine.drug - Abstract
WM/LPL is a rare distinct indolent lymphoma and the optimal management of the disease remains a major challenge. Combination therapies with old and novel agents have markedly improved the response rates and the quality of response but still the CR rates remain low and so far there is no cure. The role and timing of ASCT in the management of patients with WM/LPL has not been well established. The aim of the present study was to investigate the outcome of ASCT in early vs late WM/LPL. Methods: Eligible for this retrospective study were all patients who had a first ASCT for WM/LPL between 1995 and 2011 and were registered with the EBMT database. Baseline patient, disease, and transplant data were collected from MED-A forms. Statistical analysis used log rank tests to assess the impact of baseline characteristics on survival endpoints. Overall survival (OS) and disease-free survival (DFS) was estimated from the time of ASCT using Kaplan-Meier product-limit estimates. Curves of cumulative of non-relapse mortality (NRM) and incidence of relapse (IR) were compared by Gray’s test in a competing risk framework. Results: Altogether 615 patients fulfilling the inclusion criteria were identified in the database. The median age at ASCT was 53 years (range 19-76), and 428 patients (70%) were male. The median time from diagnosis to ASCT was 19 months (interquartile range: 10-51 months). 537 patients (71%) underwent ASCT after 2002. Disease status at ASCT was first partial (PR1), very good partial (VGPR1) or complete remission (CR1) in 325 patients, whilst 176 patients were autografted in second, third or later response, and 47 patients (4%) had primary refractory or progressive disease at ASCT. High-dose therapy was TBI-based in 82 patients (14%), and stem cell source was from peripheral blood in 598 patients (97%). With a median follow-up of surviving patients of 53 months, the 5-year OS was 65%, DFS was 46%, IR was 47% and NRM was 7%. IR was significantly lower in patients receiving ASCT in first response (CR1, VGPR1, PR1) compared to transplantation in subsequent complete or partial responses or with refractory disease (39% vs 53%; p=0.001), translating into a significant DFS (50% vs 40%, p= 0.004) and OS benefit (71% vs 63%; p= 0.033) for the patients transplanted early. DFS was significantly better for patients receiving ASCT after year 2000 compared to the patients transplanted before (p=0.031) and although the year of ASCT had influence on the OS this did not reach statistical significance (p=0.068). Multivariate analysis considering age, sex, disease status at ASCT, and ASCT year confirmed ASCT beyond 1st remission (HR 1.37, 95%CI 1.04-1.79), along with female gender (HR 0.73, 95%CI 0.54-0.97) and ASCT between 2001-2005 (vs before 2001; HR 0.66, 95%CI 0.47-0.92) as significant predictors of DFS. Conclusions: These results suggest that ASCT is a feasible and effective treatment for WM/LPL. Factors predicting for a favourable DFS are female gender, transplantation in the rituximab era, and ASCT in first remission. However, with DFS and OS of 40% and 63% at 5 years, even the outcome of patients undergoing ASCT with advanced disease is still encouraging. As single-hit ASCT can induce long term response with relatively low toxicity and economic burden, it may serve as benchmark for the upcoming novel targeted therapeutics entering the WM / LPL treatment arena. Disclosures No relevant conflicts of interest to declare.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.